Meiji Yasuda Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Meiji Yasuda Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$350K	Buy	1,452 +50	+4%	+$11K	0.02%	430
2026 Q1	$265K	Sell	1,402 -7	-0.5%	-$1.22K	0.01%	465
2025 Q4	$240K	Buy	+1,409	New	+$216K	0.01%	491
2024 Q2	–	Sell	-2,438	Closed	-$294K	–	663
2024 Q1	$294K	Buy	+2,438	New	+$299K	0.01%	545
2019 Q4	–	Sell	-1,800	Closed	-$231K	–	509
2019 Q3	$231K	Buy	+1,800	New	+$241K	0.02%	456
2019 Q2	–	Sell	-3,766	Closed	-$538K	–	503
2019 Q1	$538K	Buy	3,766 +1,566	+71%	+$204K	0.05%	346
2018 Q4	$273K	Sell	2,200 -1,600	-42%	-$237K	0.03%	426
2018 Q3	$639K	Buy	3,800 +200	+6%	+$34.4K	0.05%	319
2018 Q2	$620K	Sell	3,600 -200	-5%	-$32.7K	0.06%	329
2018 Q1	$574K	Buy	3,800 +2,000	+111%	+$293K	0.05%	341
2017 Q4	$242K	Sell	1,800 -1,400	-44%	-$194K	0.02%	463
2017 Q3	$468K	Buy	3,200 +200	+7%	+$30.2K	0.05%	366
2017 Q2	$467K	Buy	+3,000	New	+$459K	0.05%	362

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Meiji Yasuda Asset Management's JAZZ Position: Q2 2026 in Review

Meiji Yasuda Asset Management increased its Jazz Pharmaceuticals (JAZZ) stake by 3.6% in Q2 2026, buying an estimated $11K and bringing the position to 1,452 shares worth $350K. The position accounts for 0.02% of the portfolio, ranked #430.

Meiji Yasuda Asset Management first reported a position in JAZZ in Q2 2017 and has held it in 13 quarters since. The position peaked at $639K in Q3 2018. 641 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Meiji Yasuda Asset Management held 1,452 shares of Jazz Pharmaceuticals worth $350K as of Q2 2026.
Meiji Yasuda Asset Management bought 50 Jazz Pharmaceuticals shares in Q2 2026, an estimated $11K.
Jazz Pharmaceuticals made up 0.02% of Meiji Yasuda Asset Management's portfolio in Q2 2026, its #430 holding.
Meiji Yasuda Asset Management first reported a position in Jazz Pharmaceuticals in Q2 2017 and has held it in 13 quarters since.
Meiji Yasuda Asset Management's Jazz Pharmaceuticals position peaked at $639K in Q3 2018.
641 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Meiji Yasuda Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.